Breaking the persistence barrier: Alloplex Biotherapeutics to present phase 1 clinical durability data at the 11th annual Innate Killer Summit

Achieving durable responses in advanced oncology remains the most critical challenge for innate cell therapies. As the industry seeks to move beyond the limitations of singular genetic engineering, Alloplex Biotherapeutics today announced it will present data demonstrating how biological synergy can overcome tumor escape and NK cell exhaustion. At the 11th Annual Innate Killer Summit,…